https://scholars.lib.ntu.edu.tw/handle/123456789/568298
標題: | Immunologic aspects of characteristics, diagnosis, and treatment of coronavirus disease 2019 (COVID-19) | 作者: | Chang F.-Y. Chen H.-C. PEI-JER CHEN Ho M.-S. Hsieh S.-L. Lin J.-C. Liu F.-T. Sytwu H.-K. |
關鍵字: | Adaptive immunity; Antibody-dependent enhancement; COVID-19; Cytokine storm; Innate immunity; SARS-CoV; SARS-CoV-2; Vaccine | 公開日期: | 2020 | 出版社: | BioMed Central Ltd. | 卷: | 27 | 期: | 1 | 起(迄)頁: | 72 | 來源出版物: | Journal of Biomedical Science | 摘要: | On March 11, 2020, the World Health Organization declared the worldwide spread of the infectious disease COVID-19, caused by a new strain of coronavirus, SARS-CoV-2, as a pandemic. Like in all other infectious diseases, the host immune system plays a key role in our defense against SARS-CoV-2 infection. However, viruses are able to evade the immune attack and proliferate and, in susceptible individuals, cause severe inflammatory response known as cytokine storm, particularly in the lungs. The advancement in our understanding of the mechanisms underlying the host immune responses promises to facilitate the development of approaches for prevention or treatment of diseases. Components of immune system, such as antibodies, can also be used to develop sensitive and specific diagnostic methods as well as novel therapeutic agents. In this review, we summarize our knowledge about how the host mounts immune responses to infection by SARS-CoV-2. We also describe the diagnostic methods being used for COVID-19 identification and summarize the current status of various therapeutic strategies, including vaccination, being considered for treatment of the disease. ? 2020 The Author(s). |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-85085999594&doi=10.1186%2fs12929-020-00663-w&partnerID=40&md5=e391f4fad861bd6fbf18b282f2529c83 https://scholars.lib.ntu.edu.tw/handle/123456789/568298 |
ISSN: | 1021-7770 | DOI: | 10.1186/s12929-020-00663-w | SDG/關鍵字: | Chinese drug; cytokine; interferon; lianhuaqingwen; recombinant alpha interferon; ribavirin; unclassified drug; adaptive immunity; adverse event; antibody dependent enhancement; antiviral activity; clinical feature; coronavirus disease 2019; cytotoxic T lymphocyte; dendritic cell; diagnostic test; epidemic; herd immunity; human; humoral immunity; immune response; immunopathology; immunotherapy; infection prevention; infection rate; innate immunity; major histocompatibility complex; medical technology; Middle East respiratory syndrome coronavirus; plasma; priority journal; reverse transcription polymerase chain reaction; Review; Severe acute respiratory syndrome coronavirus 2; vaccination; virus entry; virus replication; virus transmission; Betacoronavirus; coronavirus disease 2019; Coronavirus infection; devices; diagnostic procedure; immunology; pandemic; physiology; virology; virus pneumonia; Betacoronavirus; Coronavirus Infections; Diagnostic Techniques and Procedures; Humans; Pandemics; Pneumonia, Viral |
顯示於: | 臨床醫學研究所 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。